The research team, led by Frederick Ifijeh of Management Sciences for Health in Abuja, together with colleagues from Asaba Specialist Hospital and the Ogun State Ministry of Health, designed the study as a sequential explanatory mixed-methods cross-sectional investigation. Between September and October 2025, the team covered all 490 functional public health facilities in Ogun State, a comprehensive sampling frame that gives the results unusual breadth for a study of this kind. The quantitative component captured 404 healthcare workers through structured questionnaires administered with KoboCollect, a mobile data collection platform built on the Open Data Kit framework. The qualitative component then followed up with 162 key informants, drawn from the same facilities, whose interviews allowed the researchers to probe the reasons behind the statistical patterns.

The headline number is stark: of the 404 healthcare workers who completed the survey, only 23, or 5.4 percent, had ever reported an adverse drug reaction in their careers. This is not merely a matter of low enthusiasm. The researchers are careful to note that because so few respondents had actually reported, the events-per-variable ratios in their regression models fell below conventional statistical thresholds, meaning the regression estimates should be read as exploratory rather than definitive. This methodological honesty matters, because it signals to readers that the true drivers of reporting behavior are best understood by triangulating the survey data with the qualitative interviews rather than relying on odds ratios alone.

Even with that caveat, the quantitative signals were consistent across both bivariate tests and multivariable logistic regression. Three factors stood out repeatedly: whether a worker had completed an adverse drug reaction reporting form before, whether suspected reactions were routinely documented in patient case notes, and whether the worker knew the channels through which reports should be submitted. In the exploratory consolidated model, routine documentation of suspected reactions, knowledge of reporting forms, time constraints, and perceived reporting burden all remained significant predictors of reporting practice. In other words, the workers most likely to report were those for whom adverse drug reaction documentation had been woven into their everyday clinical routines, and who had the practical tools and knowledge to act on a suspicion when it arose.

The qualitative interviews with 162 key informants added a sobering institutional dimension to these findings. Most informants reported receiving no pharmacovigilance training in the preceding two years, and nearly half indicated that no formal adverse drug reaction reporting system existed in their facilities at all. This is a critical distinction that the study’s authors emphasize: underreporting in Ogun State is not primarily a problem of individual motivation or ignorance among clinicians. It is a problem of infrastructure. A healthcare worker cannot file a report if the facility has no reporting forms, no designated focal person to receive them, and no established pathway to the national regulator.

Thematic analysis of the interviews, following the framework developed by Braun and Clarke, identified four principal barriers. The first is limited pharmacovigilance knowledge, meaning many workers simply do not recognize when a patient’s symptom cluster constitutes a suspected adverse reaction worth flagging. The second is weak or absent reporting systems at the facility level, which renders even well-informed workers powerless to act. The third is inadequate training and supervision, with frontline staff left without refresher courses, supportive oversight, or standard operating procedures to guide them. The fourth comprises patient-related barriers to detection, including patients who do not mention symptoms they attribute to malaria itself, who discontinue treatment without follow-up, or who seek care from informal providers outside the reporting system entirely.

The structural diagnosis has significant implications for Nigeria’s national pharmacovigilance architecture, which centers on the National Agency for Food and Drug Administration and Control, known as NAFDAC, and the National Malaria Elimination Programme. Spontaneous reporting systems depend on a chain that runs from the bedside to the regulator: a clinician must suspect a reaction, document it, complete a form, transmit it through a facility or district focal person, and eventually receive feedback confirming that the report was received and acted upon. The study suggests that in Ogun State this chain is broken at multiple links simultaneously. Without feedback from regulators, even motivated reporters receive no signal that their efforts matter, which is a well-known cause of reporting fatigue in pharmacovigilance systems worldwide.

What makes the study particularly valuable is its insistence that awareness campaigns alone will not solve the problem. The authors argue that improving adverse drug reaction reporting requires more than telling healthcare workers that reporting is important. It requires operational support: routine supervision visits, designated pharmacovigilance focal persons in every facility, consistent availability of reporting tools, and functional feedback mechanisms that close the loop between frontline reporters and the national system. Integrating adverse drug reaction documentation into routine case note workflows, so that recording a suspected reaction becomes as habitual as recording a temperature, emerges from the data as one of the most promising single interventions.

The context of malaria treatment makes these gaps especially consequential. Artemisinin-based combination therapies are administered to millions of Nigerians each year, and the emergence of drug resistance or previously unrecognized safety signals would first appear as patterns in adverse event data. If 94.6 percent of frontline providers have never filed a single report, the national surveillance system is effectively operating with a fraction of the sensitivity it needs. The authors note that underreporting driven by system-level constraints, including the lack of reporting forms, the absence of trained focal persons, weak supervision, and limited feedback from regulators, is likely to yield the greatest gains when those systems are strengthened, rather than when individual workers are exhorted to try harder.

For policymakers across malaria-endemic countries, the Ogun State findings offer a replicable template. The combination of a facility-wide quantitative survey with a large qualitative informant pool allowed the researchers to move beyond describing how rarely reporting happens and toward explaining why. The answer, in this setting, is that pharmacovigilance has been treated as an individual responsibility without being supported as an institutional function. Reversing that imbalance, through trained focal persons, reliable forms, embedded documentation routines, and visible feedback from NAFDAC and partner programs, would transform adverse drug reaction reporting from an occasional act of individual initiative into a routine, self-sustaining part of malaria case management, and would give Nigeria’s medicine safety system the early-warning capability its treatment scale demands.

Subject of Research: Determinants of adverse drug reaction reporting for antimalarial medicines among healthcare workers in Ogun State, Southwest Nigeria

Article Title: Determinants of adverse drug reaction reporting for antimalarial medicines: a mixed-methods study among healthcare workers in ogun State Southwest Nigeria

Article References: Ifijeh, F., Ejiyere, H., Babarinde, T., Adenekan, O. J., Otohabru, B., Adejo, I., Chukwuji, C., & Uko, I. (2026). Determinants of adverse drug reaction reporting for antimalarial medicines: a mixed-methods study among healthcare workers in ogun State Southwest Nigeria. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15598-5

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15598-5

Keywords: adverse drug reactions, pharmacovigilance, antimalarial medicines, malaria, healthcare workers, Nigeria, drug safety, health systems, mixed-methods research, reporting barriers, artemisinin-based combination therapies, NAFDAC

The K13 gene has been identified as a molecular marker for artemisinin resistance, a serious public health concern that threatens to undermine malaria control efforts worldwide. Since the discovery of mutations in this gene correlating with delayed parasite clearance, the scientific community has closely monitored its prevalence in malaria-endemic regions. Resistance to artemisinin and its derivatives jeopardizes treatment efficacy, necessitating urgent surveillance to inform appropriate interventions.

Iran’s situation is particularly notable, positioned geographically where malaria transmission persists in certain southern provinces. The implementation of ACTs has been the standard of care, but until now, the comprehensive genetic surveillance of K13 mutations was lacking. The present study undertook extensive sampling and genetic sequencing efforts to assess whether the widespread ACT application led to the emergence of resistance-conferring mutations within local Plasmodium falciparum populations.

The research team employed rigorous molecular techniques to amplify and sequence the K13 propeller domain from parasite isolates collected from multiple endemic regions over a significant timeframe. Their data encompassed a robust sample size, offering statistically meaningful insights into the genomic landscape of local malaria parasites. Strikingly, the investigators found no evidence of known artemisinin resistance-associated mutations in any of the isolates studied.

This outcome suggests that, despite extensive ACT exposure, Plasmodium falciparum populations in Iran have not developed genetic adaptations conferring resistance through the K13 pathway. Such a development is encouraging and highlights the effectiveness of current malaria management protocols and drug policies in the region. It also underscores the importance of continued vigilance and molecular surveillance to detect resistance at the earliest stages.

Understanding why resistance mutations have not taken hold could inform broader strategies to prevent or delay their emergence elsewhere. The complex interplay between drug pressure, parasite genetics, and transmission dynamics likely contributes to this favorable situation. For example, factors such as reduced malaria transmission intensity and the presence of fitness costs associated with resistance mutations could limit their spread.

Moreover, the study’s findings emphasize the critical role of comprehensive public health initiatives beyond pharmacological interventions. Vector control measures, rapid diagnostic testing, and patient adherence to treatment regimens collectively enhance the durability of current therapies. Iran’s malaria control program appears to effectively balance these components, contributing to the sustained sensitivity of parasites to artemisinin compounds.

The absence of artemisinin resistance-related K13 mutations also provides reassurance for clinicians and patients relying on ACTs as first-line therapy. It supports the continued use of these drugs with confidence in their capacity to clear infections effectively. However, the study’s authors caution that the situation requires ongoing monitoring given the dynamic nature of pathogen evolution and drug resistance development.

Importantly, this research contributes new data to the global map of artemisinin resistance, which has largely been driven by patterns emerging in Southeast Asia and parts of Africa. Evidence from Iran diversifies our understanding of how resistance manifests and spreads geographically, offering a comparative perspective against highly affected regions.

The molecular characterization of Plasmodium falciparum isolates featured in this study utilized cutting-edge sequencing technology, enabling precise detection of both known and novel mutations within the K13 gene. Advanced bioinformatics workflows ensured the reliability of variant calling, a crucial aspect for resistance surveillance where false positives or negatives could skew public health responses.

Additionally, the study design incorporated rigorous sampling methodologies to capture temporal and spatial variation in parasite populations. This approach strengthens confidence that the absence of detected resistance mutations reflects a true epidemiological phenomenon rather than sampling bias or technical limitations.

Given the high stakes involved in managing artemisinin resistance, the findings from Iran advance crucial knowledge for shaping regional and global malaria control policies. They suggest that maintaining integrated malaria control strategies, including robust molecular monitoring, remains vital to preserving the efficacy of ACTs.

Future research directions inspired by this work include exploring other genetic loci potentially involved in resistance mechanisms and evaluating the impact of demographic and environmental variables on parasite genetic diversity. Understanding these nuances will bolster predictive capacities and early warning systems for emergent drug resistance.

In conclusion, the recent comprehensive analysis of the Plasmodium falciparum K13 propeller domain in Iran presents optimistic news for the continued success of artemisinin-based therapies in this region. The nonappearance of mutations linked to artemisinin resistance despite widespread ACT utilization underscores the strength of existing malaria control efforts. However, it also stresses the necessity of sustained investment in molecular surveillance and integrated public health interventions to combat malaria effectively over the long term.

This landmark report not only reinforces the crucial role of genetic epidemiology in infectious disease management but also provides a beacon of hope that with vigilant and coordinated action, the tide of drug-resistant malaria can be impeded. As the global community gears up to eliminate malaria, the insights gained from Iran’s experience offer valuable lessons applicable across endemic countries.

Subject of Research: Detection of Artemisinin Resistance-Associated Mutations in the Plasmodium falciparum K13 Gene Following Widespread Use of Artemisinin-Based Combination Therapy in Iran

Article Title: Absence of Artemisinin Resistance-Associated Mutations in the Plasmodium falciparum Kelch 13 (K13) Propeller Domain Gene Following Widespread Use of Artemisinin-Based Combination Therapy in Iran

Article References:
Mohammadi, S., Forouzesh, F., Mehrizi, A.A. et al. Absence of Artemisinin Resistance-Associated Mutations in the Plasmodium Falciparum Kelch 13 (K13) Propeller Domain Gene Following Widespread Use of Artemisinin-Based Combination Therapy in Iran. Acta Parasit. 71, 5 (2026). https://doi.org/10.1007/s11686-025-01197-7

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11686-025-01197-7

Malaria remains a global health crisis, particularly in sub-Saharan Africa, where it accounts for more than 95% of the world’s cases and deaths. Despite concerted efforts to control this mosquito-borne parasitic disease, recent epidemiological data reveal a worrisome resurgence in infections and fatalities, stalling the significant progress achieved between 2000 and 2015. The World Health Organization’s most recent reports indicate that cases surged to 263 million in 2023, with fatalities close to 600,000, predominantly affecting children under five years of age.

The persistence and proliferation of drug-resistant malaria strains have been central to this stagnation. Artemisinin-based combination therapies (ACTs), once hailed as a breakthrough, are increasingly compromised by parasite resistance. Compounding this issue is the widespread patient non-compliance with the standard three-day ACT regimens, which typically require six doses administered over the period. Treatment discontinuation not only leaves infections inadequately treated but facilitates the development of resistant mutations in the parasite genome, threatening to undermine current therapeutic arsenals.

The clinical trial led by Dr. Ghyslain Mombo-Ngoma, head of clinical operations at the Medical Research Center of Lambaréné (CERMEL) in Gabon, tested an innovative therapeutic strategy combining four antimalarial agents into a single-dose protocol. This novel regimen merges sulfadoxine and pyrimethamine (SP), classic antimalarials with a long history of use, with artesunate and pyronaridine (AP), two drugs with complementary mechanisms targeting different stages of the malaria parasite. This strategic quadritherapy exploits multiple pharmacodynamic vulnerabilities of Plasmodium, thereby reducing the probability of resistance development.

Between May 2024 and October 2025, the trial enrolled over 1,000 patients diagnosed with uncomplicated malaria, nearly half of whom were children under ten. Subjects were randomized to receive either the single-dose combination of SP and AP or the standard ACT regimen of artemether-lumefantrine (AL), administered in six doses over three days. Patient outcomes were rigorously assessed via polymerase chain reaction (PCR) and microscopic examination 28 days post-treatment to quantify parasite clearance rates.

Results were compelling: 93% of patients receiving the single-dose therapy were parasite-free at 28 days, marginally surpassing the 90% clearance rate in the standard multi-dose group. Importantly, the single-dose regimen demonstrated an excellent safety profile with no serious adverse events attributable to the medications, underscoring its clinical viability. These findings suggest that the novel fixed-dose combination not only matches but may even enhance treatment efficacy while simplifying administration.

The scientific rationale for using multiple distinct antimalarial agents simultaneously is well-established in infectious disease therapy, drawing on successful precedents from managing drug-resistant tuberculosis and HIV. By applying a pharmacological “multi-front” attack, the new regimen diminishes the likelihood of parasites surviving via mutation in any one drug target pathway. Moreover, the consolidation into a single-dose format directly addresses the issue of poor adherence that plagues traditional malaria treatments, which can have fatal implications.

Critically, all four drugs employed in the study are either already widely available or poised for imminent generic production, promising scalability and accessibility in resource-limited settings. The sulfadoxine-pyrimethamine combination is a generic drug manufactured in multiple African countries. Artesunate-pyronaridine, although currently patented, is expected to become available as a generic formulation by 2026. Pharmaceutical collaborations are ongoing to develop a unified capsule or sachet encapsulating this quadruple therapy, simplifying supply chains and distribution.

The potential impact of this regimen extends beyond Gabon. Malaria research centers in neighboring African nations—including Mali, Ghana, Kenya, and Mozambique—have expressed interest in replicating these trials to validate efficacy across diverse epidemiological contexts. This geographic expansion is essential given variations in parasite genetic profiles and resistance patterns that may influence treatment outcomes.

While novel antimalarial compounds are currently under development, their widespread availability remains years away. Therefore, the current single-dose quadritherapy offers an urgently needed stopgap measure to reduce the burden of disease and stem the tide of resistance. Dr. Mombo-Ngoma emphasizes this point, noting that this approach acts as a “bridge” to the future, providing an immediate therapeutic advance while newer drugs complete clinical validation and regulatory approval.

Beyond clinical efficacy, the trial’s implications for global health practice are profound. Simplified treatment regimens can dramatically improve adherence, decrease transmission by more effectively clearing parasitemia, and reduce healthcare costs associated with repeated infections and severe disease complications. In a broader context, these advances align with international health goals aiming to eliminate malaria as a public health threat.

Dr. David Fidock, ASTMH President, highlights the importance of such innovative research, especially amid challenging global health landscapes marked by funding constraints and logistical hurdles. The study exemplifies how collaborative science continues to push the envelope in managing and ultimately conquering infectious diseases that have long plagued vulnerable populations.

As this pivotal research moves from trial data to implementation, ongoing surveillance for resistance patterns and real-world effectiveness will be critical. The integration of this single-dose treatment into national malaria control programs could redefine conventional treatment paradigms, offering hope for millions living at the epicenter of one of the world’s deadliest infectious diseases.

Subject of Research: Malaria treatment efficacy and drug resistance management
Article Title: Clinical Trial in Africa Finds Single-Dose Malaria Treatment Combining Four Existing Drugs as Effective as More Onerous Multi-Day, Multi-Dose Regimen
News Publication Date: November 12, 2025
Web References:
– American Society of Tropical Medicine and Hygiene (ASTMH): https://www.astmh.org/
– World Health Organization malaria report 2023
– Original Malaria Journal publication: https://pubmed.ncbi.nlm.nih.gov/41029666/
– WHO global malaria response context: https://www.who.int/news/item/29-11-2017-global-response-to-malaria-at-crossroads

Keywords: malaria, drug resistance, single-dose therapy, antimalarial drugs, sulfadoxine-pyrimethamine, artesunate-pyronaridine, artemisinin-based combination therapy, treatment adherence, sub-Saharan Africa, Plasmodium, clinical trial, public health innovation

Malaria remains a global health menace, with approximately 200 million cases reported annually, and P. falciparum is responsible for the majority of severe illness and fatalities. Antimalarial drugs, especially artemisinin-based combination therapies (ACTs), have formed the cornerstone of malaria treatment in endemic countries like Uganda. However, the rise of drug-resistant parasite strains threatens to undermine these gains. This investigation meticulously tracked changes in parasite susceptibility, focusing on molecular markers linked to resistance, clinical treatment outcomes, and genetic diversity among parasite populations over the course of five years.

The study utilized a robust surveillance framework encompassing both molecular and phenotypic assessments of P. falciparum isolates collected from sentinel sites across Uganda. High-throughput sequencing technologies facilitated detailed genotyping of key resistance genes, including pfkelch13—a gene widely known to confer artemisinin resistance—and pfcrt, associated with chloroquine resistance. Additionally, in vitro drug sensitivity assays measured the parasites’ growth inhibition in response to a spectrum of antimalarial compounds, providing functional corroboration to genetic findings.

One of the pivotal findings from 2019 to 2024 was an incremental increase in mutations linked to partial artemisinin resistance. This subtle yet concerning trend signals that despite the continued efficacy of ACTs in most regions, P. falciparum is gradually adapting under therapeutic pressure. Notably, mutations in the pfkelch13 gene rose from a baseline frequency of under 2% in 2019 to approximately 7% by 2024, a statistically significant change indicative of an emerging resistance phenotype. While these mutations do not yet translate to widespread treatment failure, they necessitate vigilant monitoring to preempt the establishment of fully resistant parasite populations.

Equally critical were the observations regarding partner drug susceptibility within ACT regimens. Declines in sensitivity to lumefantrine and piperaquine were detected, raising alarms about the durability of current first-line therapies. The study attributes these trends to selective pressures exerted by widespread drug use, which may inadvertently favor resistant clones. This underscores the urgency for periodic drug efficacy assessments and, potentially, the preemptive introduction of novel antimalarials or combination therapies to outpace resistance evolution.

Beyond resistance markers, the researchers documented shifts in the P. falciparum population structure. Genetic diversity analyses revealed a modest reduction in overall heterogeneity, suggesting a possible bottleneck effect driven by sustained control measures and drug pressure. Such population dynamics are crucial, as they influence the parasite’s capacity to adapt and may reflect localized success in transmission reduction. However, pockets of high genetic diversity persisted, especially in regions with inconsistent healthcare access, illuminating persistent challenges in achieving uniform malaria control.

The implications of this research extend to public health policy and malaria management. The gradual erosion of drug susceptibility in Uganda signals the need for dynamic therapeutic guidelines that adapt to evolving resistance patterns. The study advocates for integrating resistance marker surveillance into routine malaria monitoring programs, enabling real-time data-driven decisions. Furthermore, the authors emphasize strengthening community-based interventions to mitigate transmission hotspots that act as reservoirs for resistant parasites.

Crucially, this research exemplifies the power of collaborative, multidisciplinary approaches in tackling malaria. It combined epidemiological data, molecular biology, and clinical insights from government health agencies, academic institutions, and frontline healthcare workers. Such integrated efforts are paramount in constructing a detailed, actionable picture of resistance trends and their impact on treatment efficacy.

In addition to surveillance, the study promotes the acceleration of antimalarial drug development pipelines. Resistance to currently deployed compounds, even if still emergent, threatens to reverse decades of progress. Investment in novel classes of antimalarials that bypass known resistance mechanisms or target different parasite life cycle stages is imperative. The research team highlights promising candidates in early clinical trials, but warns that their widespread deployment must be coupled with robust stewardship to preserve their efficacy.

The findings also spotlight the role of genomic technologies in infectious disease control. Advanced sequencing and bioinformatics enabled high-resolution tracking of resistance mutations and parasite population changes over time. This technological prowess empowers researchers and public health officials to anticipate resistance trajectories and implement preemptive measures—a paradigm shift from reactive to proactive malaria management.

Moreover, the study’s geographic focus on Uganda offers valuable lessons for other malaria-endemic regions. Uganda’s diverse epidemiological landscape, ranging from high-transmission rural areas to urban centers with variable health infrastructure, provides a microcosm for understanding resistance dynamics in sub-Saharan Africa. Insights gained here can inform tailored interventions elsewhere, recognizing that one-size-fits-all approaches may falter amid local diversity.

The research also addresses the social and economic dimensions influencing resistance emergence. It acknowledges that inconsistent drug quality, substandard dosing, and self-medication practices contribute to selective pressures that drive resistance. Strengthening pharmaceutical regulation and community education is therefore integral to comprehensive resistance mitigation strategies.

Furthermore, the study underscores the importance of sustained funding in malaria control research. Longitudinal, high-resolution datasets are expensive and logistically challenging to maintain but essential for capturing the nuanced evolution of parasite susceptibility. The authors call on global health agencies and donors to prioritize continuous surveillance frameworks rather than episodic investigations.

Finally, the emerging data from 2019 to 2024 offer a cautiously optimistic narrative. Although resistance markers have increased, current ACTs largely remain efficacious, and intensified control measures appear to suppress transmission intensity in several regions. This window of opportunity should galvanize intensified efforts to preempt resistance-driven treatment failures and sustain the momentum towards malaria elimination.

In conclusion, this landmark study illuminates the shifting battleground in Uganda’s fight against malaria, revealing early warning signs of drug resistance evolution in Plasmodium falciparum. Its nuanced insights into genetic, phenotypic, and epidemiological changes underscore the complexity of managing antimalarial drug efficacy in real-world settings. The research serves as both a scientific beacon and a clarion call for adaptive, integrated strategies combining surveillance, drug development, policy reform, and community engagement to sustain and accelerate malaria control achievements globally.

Subject of Research: Changes in susceptibility of Plasmodium falciparum to antimalarial drugs over time in Uganda.

Article Title: Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019–2024.

Article References:
Okitwi, M., Orena, S., Tumwebaze, P.K. et al. Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019–2024. Nat Commun 16, 7353 (2025). https://doi.org/10.1038/s41467-025-62810-x

Image Credits: AI Generated